Strategic Advisory Committee

Mary Tresgallo, DNP, MPH, FNP-BC

Dr. Mary Tresgallo, DNP, MPH, FNP-BC, ACHPN

Columbia University Medical Center – Assistant Professor of Nursing & Chairman of Pediatric Ethics Committee NewYork-Presbyterian Morgan Stanley Children’s Hospital (NYP-MSCH).

Mary Tresgallo has spent her career on the front lines of Medicine and Nursing in cancer care at both Columbia University Medical Center and Memorial Sloan Kettering Cancer Center in NYC. She has extensive clinical experience in the care of critically ill adults and children in the areas of hematology/oncology, intensive care, cardiology and pediatric pain, symptom management and palliative care.

Mary is a faculty member at Columbia University College of Physicians and Surgeons Program in Women and Children’s Bioethics.  Her focus has been on bioethics, acute pain management and palliative care for children. She also currently serves as a pediatric ethics consultant at NYP-MSCH.

As Chairman of the Pediatric Ethics Committee for the NewYork Presbyterian – Morgan Stanley Children’s Hospital, which ranked in the Top 50 hospitals for all 10 pediatric specialties in U.S. News and World report, Mary works closely with pediatric hematologists and oncologists on ethical issues that may arise during cancer treatment and research.

In addition to her faculty and ethics work, Mary is a member of the admissions committee for the Medical School for International Health at Ben-Gurion University of the Negev.  Mary has authored and published a dozen papers in leading medical journals as well as co-authored book chapters.

Mary received three degrees from Columbia University, including: Doctor of Nursing Practice, Master of Public Health, and Master of Science. She has advanced certification in Hospice and Palliative Nursing.

Martin Kleckner III
Senior Vice President/Chief Operations Officer; Managing Principal/NSF I-Corps Adjunct Faculty

Senior level expertise in corporate management, business development, marketing, strategic accounts, asset management, growth strategy, new initiative start-up and development, cost & productivity, cost effectiveness, finance, operations, sales/marketing, business development (emerging technology), and partnerships/mergers/acquisitions. Work performed for Fortune 100/500 companies throughout Europe, Asia, and the Americas.

Expertise: Business & market development, business economics, organization design & development, change management & turnaround initiatives, asset management, and disruptive technologies. Emerging technology businesses: Chief executive, founder, interim executive, & advisor; new tech escort – market and competitor due diligence and business plan development. Raise capital: angel networks and venture groups, corporate partnerships and investments, federal grants, congressional funding. Form business alliances, recruit key executives and achieve critical commercialization milestones through the planned liquidity event.

Commercialization advisor to government agencies, foundations and universities: emerging tech assessments, licensing, market appraisal and business development. Develop commercialization partners and recruit investors. Grant proposal assessments – early stage technology and intellectual property assessment, designed to rapidly and cost-efficiently identify significant barriers to commercialization before resources are spent on a technology which is unlikely to succeed. Responsibilities include NIH and private foundation grant recipient translation/commercialization support, company formation, technology niche analysis, market intelligence, venture due diligence. Guidance comprises product positioning and branding, business and revenue model, competitive openings and tactics, intellectual property, payer reimbursement, FDA regulations and policies.

Recent Articles

Oriana Sousa, 28, who lives in Marinha Grande, Portugal, had a rare, aggressive form of ovarian cancer. Traditional trea...
The science of using immunotherapy to treat cancer is advancing rapidly, marked by the National Cancer Institute’s rec...
The science of using immunotherapy to treat cancer is advancing rapidly, marked by the National Cancer Institute’s rec...
A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why...